JPMorgan Chase & Co. set a GBX 5,800 ($77.22) price objective on AstraZeneca (LON:AZN) in a report issued on Monday, May 28th. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Other equities research analysts have also issued reports about the company. Berenberg Bank raised their price objective on AstraZeneca from GBX 5,800 ($77.22) to GBX 6,000 ($79.88) and gave the stock a buy rating in a research note on Thursday, February 8th. BNP Paribas restated an outperform rating and set a GBX 5,600 ($74.56) target price on shares of AstraZeneca in a report on Thursday, March 22nd. Kepler Capital Markets restated a buy rating and set a GBX 5,250 ($69.90) target price on shares of AstraZeneca in a report on Tuesday, January 30th. Barclays reiterated a top pick rating and issued a GBX 6,300 ($83.88) price objective on shares of AstraZeneca in a research note on Monday, February 5th. Finally, Credit Suisse Group reiterated an outperform rating and issued a GBX 5,800 ($77.22) price objective on shares of AstraZeneca in a research note on Tuesday, February 20th. Four investment analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have issued a buy rating to the stock. The company has an average rating of Hold and a consensus price target of GBX 5,321.39 ($70.85).

AZN traded up GBX 89 ($1.18) during trading hours on Monday, hitting GBX 5,448 ($72.53). The company’s stock had a trading volume of 2,055,169 shares, compared to its average volume of 2,310,000. AstraZeneca has a fifty-two week low of GBX 4,260 ($56.72) and a fifty-two week high of GBX 5,520 ($73.49).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with's FREE daily email newsletter.